Form 4: Immunovant's Chief Legal Officer Receives Stock and Options Grant

Christopher Van Tuyl, Immunovant's Chief Legal Officer, was granted restricted stock units and stock options on December 16, 2024, under the company's 2019 Equity Incentive Plan.

Summary

• On December 16, 2024, Christopher Van Tuyl, the Chief Legal Officer of Immunovant, Inc., received 109,956 restricted stock units (RSUs) and an option to purchase 137,446 shares of common stock.
• The RSUs and options were granted under Immunovant's 2019 Equity Incentive Plan.
• The RSUs will vest as to 25% on December 16, 2025, and the remaining 75% will vest in 12 successive substantially equal quarterly installments over the following three years, contingent upon continuous service to Immunovant.
• The options have an exercise price of $27.63 and will vest according to the same schedule as the RSUs, with 25% vesting on December 16, 2025, and the remainder vesting quarterly over the subsequent three years, also subject to continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs and stock options aligns the Chief Legal Officer's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment to Immunovant over a four-year period.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with those of the shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Equity compensation packages for Chief Legal Officers in the biotechnology industry typically include a mix of stock options and restricted stock units.
• The size of the grant is likely determined by factors such as company size, stage of development, and individual performance.
• Comparable companies such as Argenx, UCB, and Johnson & Johnson also use equity grants as part of their compensation strategy.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates